Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 18Neoplasm Metastasis 10Triple Negative Breast Neoplasms 9Lung Neoplasms 9Ovarian Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Endometrial Neoplasms 6Fallopian Tube Neoplasms 5Uterine Cervical Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Neoplasms 3Cholangiocarcinoma 3Adenocarcinoma 3Stomach Neoplasms 2Oropharyngeal Neoplasms 2Mouth Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Biliary Tract Neoplasms 2Anatomic Stage I Breast Cancer AJCC v8 2Vulvar Neoplasms 1Vomiting 1Uterine Neoplasms 1Small Cell Lung Carcinoma 1Sinonasal Squamous Cell Carcinoma 1Recurrence 1Pancreatic Ductal Adenocarcinoma (PDAC) 1Pancreatic Cystic Neoplasm 1Pancreatic Adenocarcinoma Metastatic 1

Interventions

beta-D-glucosylisophosphoramide mustard 1Telemedicine 1Taxes 1Practice Guidelines as Topic 1Gemcitabine 1Fluorouracil 1Counseling 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Metastatic Pancreatic Adenocarcinoma × Taxes × Clear all
NCT06576115 2025-11-05

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

Barbara Ann Karmanos Cancer Institute

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡